Davunetide
Davunetide (NAP, ADNP-derived peptide)
Also known as: NAP, AL-108
A neuroprotective peptide fragment studied in humans for neurodegenerative disease, with a failed pivotal trial but ongoing interest.
Overview
Davunetide is an eight-amino-acid fragment of activity-dependent neuroprotective protein (ADNP) that stabilizes the neuronal cytoskeleton. It reached human trials for cognitive and neurodegenerative conditions; a pivotal Phase 2/3 study in progressive supranuclear palsy did not meet its endpoints. Research interest continues in ADNP-related disorders. It is not approved.
Mechanism of action
Stabilizes microtubules and tau-related cytoskeletal structure in neurons, supporting neuronal integrity.
Key studies & citations
- Human2014
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
313 patients over 52 weeks: no difference from placebo on PSP Rating Scale or daily-living scale; not an effective treatment for PSP.
The Lancet Neurology - Human2012
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
Well tolerated; no significant effect on MCCB cognition, with a modest signal on functional capacity (UPSA).
Schizophrenia Research
Frequently asked questions
Is davunetide effective?
Its main human trial did not meet its endpoints. It remains a research peptide of interest in specific ADNP-related conditions but is not approved.